1. Scrip
  2. >>Business

Tecentriq Disappoints In Post-Surgery Bladder Cancer

Fails To Hit Disease-Free Survival

 
• By Andrew McConaghie

Failure is a knock-back for the blockbuster product, but Tecentriq has many more opportunities for trial success in 2020.

Roche

Roche’s attempts to expand the use of its immunotherapy Tecentriq across a broad range of adjuvant (post-surgery) uses has been hit by disappointing results in bladder cancer.

The company has announced that its Phase III IMvigor010 study looking at Tecentriq (atezolizumab) as an adjuvant monotherapy treatment did not meet its primary endpoint of disease-free survival (DFS) compared...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Novo Nordisk’s CEO forced out; quantifying biopharma’s contribution to the US economy; a history of MASH deals; lift for AstraZeneca’s asthma ambitions; and major Japanese firms see US revenue growth.

Ascentage Broadens Horizons As Pipeline Shows Renewed Promise

 
• By Xu Hu

Ascentage will share at ASCO new clinical data on its Bcl-2 inhibitor lisaftoclax, part of the Chinese firm's novel pipeline, on which its CEO shared with Scrip plans and strategy, along with some views on the use of RWD in China.

Tech Convergence, Quality Data Needed To Accelerate Korea’s AI-Powered R&D

 
• By Jung Won Shin

AI-powered drug development was a major topic at the recent Bio Korea meeting, where experts discussed how the technology is changing R&D activities and the challenges being faced by Korean firms as they look to catch up with their global competitors.